Table 7.
Current clinical trials of HDACis as a combination therapy in GBM
| HDACis | synergistic members | conditions | phase | trial identifier | reference |
|---|---|---|---|---|---|
| Vorinostat (SAHA) | Bevacizumab | Recurrent GBM | phase II | NCT01738646 | [213] |
| Bevacizumab, Temozolomide | Recurrent Malignant Gliomas | phase I/II | NCT00939991 | [214] | |
| Temozolomide | Malignant Gliomas | phase I | NCT00268385 | [215] | |
| Radiation | Recurrent Glioma | phase I | NCT01378481 | - | |
| Isotretinoin, Temozolomide | Recurrent GBM | phase I/II | NCT00555399 | - | |
| Erlotinib, Temozolomide | Recurrent GBM | phase I/II | NCT01110876 | - | |
| Temozolomide, Radiation | Newly Diagnosed GBM | phase I/II | NCT00731731 | [216] | |
| Pembrolizumab, Temozolomide | Newly Diagnosed GBM | phase I | NCT03426891 | - | |
| Bortezomib | Recurrent GBM | phase II | NCT00641706 | [217] | |
| Bevacizumab, Irinotecan | Recurrent GBM | phase I | NCT00762255 | [218] | |
| Panobinostat (LBH-589) | Bevacizumab | Recurrent High Grade Glioma | phase I/II | NCT00859222 | [219] |
| Radiation | Recurrent Glioma | phase I | NCT01324635 | - | |
| Valproate (valproic acid, VPA) | Sorafenib Tosylate, Sildenafil Citrate | Recurrent High-Grade Glioma | phase II | NCT01817751 | - |
| Temozolomide, Radiation | High Grade Gliomas | phase II | NCT00302159 | [220–222] | |
| Nivolumab, Radiation | Recurrent GBM | phase I | NCT02648633 | - | |
| Belinostat (PXD101) | Temozolomide, Radiation | GBM | phase II | NCT02137759 | - |